Under pressure from shareholders, BioCryst drops plan to merge with Idera
BioCryst is backpedaling hard from its proposed merger agreement with Idera following an outcry from shareholders this spring. The Durham, North Carlina-based company said Tuesday evening after the market closed that the merger is officially off.
The retraction comes a few months after BioCryst $BCRX announced it would join up with Research Triangle Park company Idera $IDRA. Together, they would rebrand and focus on their combined rare disease programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
